{
  "citations" : [ {
    "@id" : "https://pharmgkb.org/literature/7283333",
    "@context" : "https://api.pharmgkb.org/jsonld/literature.jsonld",
    "id" : 7283333,
    "title" : "Pharmacogenetics: from bench to byte--an update of guidelines.",
    "_sameAs" : "https://www.ncbi.nlm.nih.gov/pubmed/21412232",
    "authors" : [ "Swen J J", "Nijenhuis M", "de Boer A", "Grandia L", "Maitland-van der Zee A H", "Mulder H", "Rongen G A P J M", "van Schaik R H N", "Schalekamp T", "Touw D J", "van der Weide J", "Wilffert B", "Deneer V H M", "Guchelaar H-J" ],
    "crossReferences" : [ {
      "@id" : "https://pharmgkb.org/crossReference/pubMed/21412232",
      "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
      "id" : 769250885,
      "resource" : "PubMed",
      "resourceId" : "21412232",
      "_url" : "https://www.ncbi.nlm.nih.gov/pubmed/21412232",
      "version" : 0
    }, {
      "@id" : "https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34",
      "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
      "id" : 1449247827,
      "resource" : "DOI",
      "resourceId" : "10.1038/clpt.2011.34",
      "_url" : "http://dx.doi.org/10.1038%2Fclpt.2011.34",
      "version" : 0
    } ],
    "hasKeyword" : true,
    "journal" : "Clinical pharmacology and therapeutics",
    "meshDiseases" : [ ],
    "meshTerms" : [ "Animals", "Aryl Hydrocarbon Hydroxylases", "Cytochrome P-450 CYP2C9", "Drug Administration Schedule", "Drug-Related Side Effects and Adverse Reactions", "Humans", "Pharmaceutical Preparations", "Pharmacogenetics", "Practice Guidelines as Topic" ],
    "month" : 5,
    "nonHuman" : false,
    "objCls" : "Literature",
    "page" : "662-73",
    "pediatric" : false,
    "pgkbPublication" : false,
    "pubDate" : "2011-05-01T00:00:00-07:00",
    "summary" : "Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch Association for the Advancement of Pharmacy established the Pharmacogenetics Working Group with the objective of developing pharmacogenetics-based therapeutic (dose) recommendations. After systematic review of the literature, recommendations were developed for 53 drugs associated with genes coding for CYP2D6, CYP2C19, CYP2C9, thiopurine-S-methyltransferase (TPMT), dihydropyrimidine dehydrogenase (DPD), vitamin K epoxide reductase (VKORC1), uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), HLA-B44, HLA-B*5701, CYP3A5, and factor V Leiden (FVL).",
    "version" : 2,
    "volume" : "89",
    "year" : 2011
  } ],
  "guideline" : {
    "@id" : "https://pharmgkb.org/guidelineAnnotation/PA166104979",
    "@context" : "https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld",
    "objCls" : "Guideline Annotation",
    "id" : "PA166104979",
    "name" : "Annotation of DPWG Guideline for acenocoumarol and CYP2C9",
    "cancerGenome" : false,
    "crossReferences" : [ ],
    "guidelineGenes" : [ ],
    "history" : [ {
      "id" : 1183704436,
      "date" : "2011-08-10T00:00:00-07:00",
      "type" : "Create",
      "version" : 0
    }, {
      "id" : 1450414926,
      "date" : "2019-05-23T08:54:07.271-07:00",
      "description" : "Annotation current with November 2018 DPWG Guideline release",
      "type" : "Update",
      "version" : 0
    }, {
      "id" : 1450820419,
      "date" : "2019-09-25T00:00:00-07:00",
      "description" : "No changes based on August 2019 guidelines",
      "type" : "Update",
      "version" : 0
    }, {
      "id" : 1450956221,
      "date" : "2020-01-31T13:16:09.847-08:00",
      "description" : "Updated link to 2011 DPWG methods",
      "type" : "Update",
      "version" : 0
    }, {
      "id" : 1450962485,
      "date" : "2020-02-10T08:20:58.467-08:00",
      "description" : "Fixed links to 2018 guideline pdfs.",
      "type" : "Update",
      "version" : 0
    }, {
      "id" : 1451704217,
      "date" : "2022-03-03T16:33:29.668-08:00",
      "description" : "Annotation current with May 2021 DPWG Guideline release",
      "type" : "Note",
      "version" : 0
    }, {
      "id" : 1451732857,
      "date" : "2022-03-28T09:57:43.484-07:00",
      "description" : "Annotation current with February 2022 DPWG guideline release",
      "type" : "Note",
      "version" : 0
    } ],
    "literature" : [ {"@id":"https://pharmgkb.org/literature/7283333","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":7283333,"title":"Pharmacogenetics: from bench to byte--an update of guidelines.","_sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/21412232","crossReferences":[{"@id":"https://pharmgkb.org/crossReference/pubMed/21412232","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":769250885,"resource":"PubMed","resourceId":"21412232","_url":"https://www.ncbi.nlm.nih.gov/pubmed/21412232"},{"@id":"https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449247827,"resource":"DOI","resourceId":"10.1038/clpt.2011.34","_url":"http://dx.doi.org/10.1038%2Fclpt.2011.34"}],"objCls":"Literature"}, {"@id":"https://pharmgkb.org/literature/15102465","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":15102465,"title":"Dutch Pharmacogenetics Working Group Guidelines November 2018","_sameAs":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","crossReferences":[{"@id":"https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1450415575,"resource":"URL","resourceId":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","_url":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"}],"objCls":"Literature"} ],
    "pediatric" : false,
    "recommendation" : false,
    "relatedAlleles" : [ {
      "@id" : "https://pharmgkb.org/haplotype/PA165816543",
      "@context" : "https://api.pharmgkb.org/jsonld/haplotype.jsonld",
      "objCls" : "Haplotype",
      "id" : "PA165816543",
      "symbol" : "CYP2C9*2",
      "name" : "*2",
      "version" : 19
    }, {
      "@id" : "https://pharmgkb.org/haplotype/PA165816544",
      "@context" : "https://api.pharmgkb.org/jsonld/haplotype.jsonld",
      "objCls" : "Haplotype",
      "id" : "PA165816544",
      "symbol" : "CYP2C9*3",
      "name" : "*3",
      "version" : 21
    } ],
    "relatedChemicals" : [ {
      "@id" : "https://pharmgkb.org/chemical/PA452632",
      "@context" : "https://api.pharmgkb.org/jsonld/chemical.jsonld",
      "objCls" : "Chemical",
      "id" : "PA452632",
      "name" : "acenocoumarol",
      "version" : 7
    } ],
    "relatedGenes" : [ {
      "@id" : "https://pharmgkb.org/gene/PA126",
      "@context" : "https://api.pharmgkb.org/jsonld/gene.jsonld",
      "objCls" : "Gene",
      "id" : "PA126",
      "symbol" : "CYP2C9",
      "name" : "cytochrome P450 family 2 subfamily C member 9",
      "version" : 7876
    } ],
    "source" : "DPWG",
    "summaryMarkdown" : {
      "id" : 1447981944,
      "html" : "<p>There are currently no recommendations for acenocoumarol dosing based on CYP2C9 genotypes.</p>\n",
      "version" : 1
    },
    "terms" : [ ],
    "textMarkdown" : {
      "id" : 1447981943,
      "html" : "<h3 id=\"november-2018-update\">November 2018 Update</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for acenocoumarol based on CYP2C9 genotypes. They conclude that no action is needed for this gene-drug interaction. <em>See the <a href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\">Dutch guidelines November 2018 update</a>.</em></p>\n<p>The annotation of the DPWG guideline for acenocoumarol and VKORC1 can be found <a href=\"https://www.pharmgkb.org/guidelineAnnotation/PA166104938\">here</a>.</p>\n<p><a rel=\"noopener noreferrer\" href=\"https://www.g-standaard.nl/risicoanalyse/B0001868.PDF\" target=\"_blank\">Read for more information about this recommendation</a>, <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Read about gene information from DPWG</a></p>\n<h3 id=\"2011-guideline\">2011 Guideline</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for acenocoumarol based on CYP2C9 genotype [Article:<a href=\"/pmid/21412232\">21412232</a>].</p>\n<table class=\"table\">\n<thead>\n<tr><th>Genotype</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>\n</thead>\n<tbody>\n<tr><td>CYP2C9 *1/*2</td><td>Check INR more frequently after initiating or discontinuing NSAIDs</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms females, &lt;470 ms males); INR increase &lt;4.5. Kinetic effect (S)</td></tr>\n<tr><td>CYP2C9 *2/*2</td><td>Check INR more frequently after initiating or discontinuing NSAIDs</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms females, &lt;470 ms males); INR increase &lt;4.5. Kinetic effect (S)</td></tr>\n<tr><td>CYP2C9 *1/*3</td><td>Check INR more frequently after initiating or discontinuing NSAIDs</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): short-lived discomfort (&lt; 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia &gt; 1.5x10<sup>9</sup>/l; leucopenia &gt; 3.0x10<sup>9</sup>/l; thrombocytopenia  &gt; 75x10<sup>9</sup>/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test.</td></tr>\n<tr><td>CYP2C9 *2/*3</td><td>Check INR more frequently after initiating or discontinuing NSAIDs</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms females, &lt;470 ms males); INR increase &lt;4.5. Kinetic effect (S)</td></tr>\n<tr><td>CYP2C9 *3/*3</td><td>Check INR more frequently during dose titration and after initiating or discontinuing NSAIDs</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms females, &lt;470 ms males); INR increase &lt;4.5. Kinetic effect (S)</td></tr>\n</tbody>\n</table>\n<ul>\n<li>*See <a href=\"http://www.pharmgkb.org/page/dpwg\">Methods </a> or [Article:<a href=\"/pmid/18253145\">18253145</a>] for definition of &quot;good quality.&quot;</li>\n<li>S: statistically significant difference.</li>\n<li>Please see attached PDF for detailed information about the evaluated studies: <a href=\"https://api.pharmgkb.org/v1/download/file/attachment/acenocoumarol_CYP2C9_271111.pdf\">Acenocoumarol CYP2C9 </a></li>\n</ul>\n",
      "version" : 12
    },
    "userId" : "jmbarbarino",
    "version" : 23
  }
}